INTRODUCTION

There are a large number of signal molecules involved in the regulation of the hair cycle and regeneration of hair follicle (HF). Those include genes, growth factors, nuclear receptors, cytokines, and subcellular signaling pathways. Growth factors that control the HF development and growth cycle are epidermal growth factor (EGF), transforming growth factor (TGF), keratinocyte growth factor (KGF), and vascular endothelial growth factor (VEGF).[1] Some of these growth factors responsible for anagen phase initiation (KGF& VEGF), others suppress growth and differentiation of HF in telogen and catagen phases (TGF β, EGF). Thus, growth factors can be key molecules that participate in the initiation and suppression of normal hair growth cycle.[3]

Although hair growth factors are important for HF physiological growth, its dysregulation may have a role in hair disorders. The roles of EGF and EGFR in the pathogenesis of alopecia areata (AA) are unknown. However, reports have suggested an association between EGF and its receptor (EGFR) signaling and AA.[4] The
pathogenesis of AA is incompletely understood, though it is believed to result, at least in part, from a loss of immune privilege in the HF, autoimmune HF destruction, and upregulation of inflammatory pathways.[8] We can clarify the other face in AA pathogenesis is the dysregulation of hair growth factors as some are well approved as TGF β1 and others not well known and need more work as EGF.

In AA, hair shedding occurs even before the anagen starts leaving the HF empty (kenogen). Thus, AA is generally a disorder of hair cycling and is considered to be a persistent state of kenogen.[9] However, the exact genes involved in hair loss are not clearly known, and some of the proposed genes responsible for hair growth are desmoglein, activin, EGF, fibroblast growth factor, lymphoid enhancer-binding factor-1, and sonic hedgehog.[7]

The EGF promotes the growth of the outer root sheath (ORS) compartment of mink HF’s and enhances the proliferation and migration of ORS cells through the activation of the Wnt/β-catenin signaling pathway.[6] However, with the completion of follicular growth, normal expression of EGF and EGFR in ORS is downregulated, and continuous expression of EGF in HF’s of transgenic mice arrested follicular growth and development at the final stage of morphogenesis.[9]

The polymorphism of EGF was correlated with the pathogenesis of AA as it caused the compensatory expression of EGF. The elevation of EGF inhibits the induction of anagen phase and decreases hair shaft elongation. The polymorphism of EGFR may cause functional deceleration of protein-like EGFR inhibitor and thus modulate the expression of immune molecules.[4] EGFR inhibitors lead to the disorganized formation of the HF and manifest as abnormalities such as finer, curlier, and more brittle hair and both scarring and nonscarring alopecia.[10] Hence, elevated EGF as a compensatory effect of receptor polymorphism, block, inhibition, or increased competitors as TGF may be involved in AA pathogenesis through its direct effect on HF, nonfunctioning hair growth factor, or through immunological mechanisms.

**SUBJECTS AND METHODS**

**Study population**

This case–control study included 60 clinically diagnosed patients with AA with different variants and severities and 25 age- and sex-matched healthy controls. Patients were selected from the outpatient clinic of the Dermatology Department. Written informed consent was taken before the start of the study, which is approved by the Ethics Committee for Human Research. This protocol of research work was in accordance with the Helsinki Declaration of Human Rights 1975.

Patients with scarring and other nonscarring alopecia and patients suffering from thyroid diseases, autoimmune diseases, infectious diseases, tumors, and hyperandrogenism were excluded. Each patient was subjected to complete history taking, general examination, and clinical assessment of AA lesions to assess site, number, size, and severity. The severity of AA was assessed by the Severity of Alopecia Tool score.[11]

**Blood samples and quantification of epidermal growth factor**

Blood samples were collected in complete aseptic condition by venipuncture, and then, blood was left to clot and then centrifuged for 15 min at 5000 rpm. The sera were separated and stored at −20°C until the time of the assay. This ELISA kit uses a double-antibody sandwich ELISA to assay the level of EGF in samples, from Sun Red Biotechnology Company, made in Shanghai, China, Catalog no. 201-12-0145.

**Statistical analysis**

All data were collected, tabulated, and statistically analyzed using SPSS 20.0 for windows (SPSS Inc., Chicago, IL, USA, 2011). Quantitative data were expressed as the mean ± standard deviation and minimum–maximum, and qualitative data were expressed as absolute frequencies (number) and relative frequencies (percentage). Continuous data were checked for normality using Shapiro–Wilk test. Mann–Whitney U-test was used for comparing two groups of not normally distributed variables. Kruskal–Wallis test was used to compare between more than two groups of nonnormally distributed variables. The percentage of categorical variables was compared using Chi-square test. Logistic regression analysis was used to determine the predictors of AA. All tests were two-sided. P < 0.05 was considered statistically significant and P ≥ 0.05 was considered statistically insignificant.

**RESULTS**

We found that the mean serum EGF was statistically significantly higher in patients (57.3 ± 64.8) than that of controls (18.9 ± 16) (P < 0.0003) [Table 1].
El-Refai, et al.: Elevated EGF: A marker of severity, recurrence, and bad prognosis in AA

The EGF level was higher in patients with disease duration >1 month (67.5 ± 74) than patients with disease duration ≤1 month (47 ± 53.5). Furthermore, EGF was lower in patients with previous treatment (52 ± 65) than patients with no previous treatment (60.8 ± 65), and it was higher in patients with no response to previous treatment (32.7 ± 28); it was higher in patients with high recurrence (68.4 ± 76.6) than patients without recurrence (50.8 ± 57) (P > 0.05) [Table 2].

The EGF in patients of severe AA was statistically significantly higher than moderate AA patients, and moderate cases were higher than mild AA patients (P = 0.0001) [Table 3]. There was a statistically significant difference of EGF level regarding the type of lesions. The highest level of mean EGF level in Alopecia universalis followed by Alopecia totalis then higher number of lesions, the difference was statistically significant (P = 0.003). Furthermore, the level of EGF ng/ml was different with scalp involvement; the highest level in S4 hair loss was 221.8 ± 16.8 ng/ml. Then, S3 the EGF level was 113.4 ± 117.2 ng/ml, followed by different percentage of hair loss, the difference was statistically significant (P = 0.007). The EGF level of B0 was 60.0 ± 67.7 and B1 32.7 ± 24.7 with statistically insignificant difference (P = 0.27) [Table 4].

**DISCUSSION**

The results of this study showed that the serum level of EGF was significantly higher in patients with AA compared to healthy controls (P < 0.0003). This was in agreement with a study conducted by Wilkening et al.[4] which suggested that EGF and EGFR could be associated with the pathogenesis of AA. As studied the association between EGF and EGFR gene polymorphisms and susceptibility to AA in the Korean population, their results were one SNP (rs11569017) of EGF which showed a significant difference between the AA group and the control group.

The effects of EGF on the homeostasis of the HF were matter of great debates. This study showed that EGF had a negative effect on HF growth and may be linked to AA pathogenesis. This may be explained as the EGF binds to ErbB1 and participates in regulating DNA synthesis rate of ORS cells and hair bulb cells of HF, so that the HFs enter regression period in advance from growth period.[12] In the early stages of HF growth, EGF and/or TGF-α can inhibit HF formation, which are greatly related with ErbB1.[13] In human HF culture, EGF and EGFR showed a capacity for inhibiting hair shaft elongation and changing the morphology to catagen growth pattern by suppressing mitotic regulators including Rcc2 and Statnph1.14,15 The EGF receptor mediates the termination of the anagen stage.[10] The EGF injection in sheepskin produced hair

**Table 1: Comparison between alopecia areata patients and controls as regards epidermal growth factor level**

| Item                  | Studied groups | MW     | P           |
|-----------------------|----------------|--------|-------------|
|                       | AA patients (n=60) | Controls (n=25) |            |
| EGF                   | Mean±SD        |        | 4.3         |
|                       | 57.3±64.8      | 18.9±16| 0.0002      |
| Minimum-maximum       | 1.8-232.1      | 0.18-77.1| (S)         |

AA – Alopecia areata; EGF – Epidermal growth factor; MW – Mann-Whitney U-test; S – Significant; SD – Standard deviation

**Table 2: Comparison between alopecia areata patients’ epidermal growth factor level as regards duration, previous treatment, previous response, and recurrence**

| Items                              | n (%) | EGF | MW     | P         |
|------------------------------------|-------|-----|--------|-----------|
|                                    |       | Mean±SD | Minimum-maximum |           |
|                                    |       |         |          |           |
| Disease duration (month)           |       |        |          |           |
| ≤1                                 | 30 (50)| 47.5±53.5| 10.7-200.8 | 1.1       | 0.28 (NS) |
| >1                                 | 30 (50)| 67.5±74  | 1.8-232.1  |           |           |
| Previous treatment                 |       |        |          |           |
| Yes                                | 24 (40)| 52±65  | 10.7-232.1 | 1.5       | 0.14 (NS) |
| No                                 | 36 (60)| 60.8±65| 15-225.8  |           |           |
| Response to previous treatment     |       |        |          |           |
| Yes                                | 16 (66.7)| 32.7±28| 10.7-127.4 | 0.7       | 0.49 (NS) |
| No                                 | 8 (33.3)| 90.7±98.3| 12.3-232.1 |           |           |
| Recurrence                         |       |        |          |           |
| Yes                                | 22 (36.7)| 68.4±76.6| 1.8-220.6  | 0.1       | 0.9 (NS)  |
| No                                 | 38 (63.3)| 59.8±57| 12.6-225.8 |           |           |

EGF – Epidermal growth factor; MW – Mann-Whitney U-test; S – Significant; SD – Standard deviation; NS – Insignificant
El-Refai, et al.: Elevated EGF: A marker of severity, recurrence, and bad prognosis in AA

loss and epidermal thickening.\textsuperscript{[14]} EGF, which produces hyperproliferation of the basal cell layers, causes arrest of the HF development.\textsuperscript{[17]} Philpott and Kealey\textsuperscript{[18]} studied the effect of EGF on cells of ORS of isolated human HF and suggested that EGF may play a role in transition from anagen to catagen. Furthermore, Hansen et al.\textsuperscript{[19]} suggested that the EGF receptor mediates the termination of the anagen stage.

By indirect way, trichomegaly was coincidence during treatment with the EGFR inhibitors cetuximab, erlotinib, and gefitinib. The sustained increases in hair growth suggested that decreased EFG can stimulate HF growth.\textsuperscript{[20]}

It was also found that men with androgenic alopecia had a reduction in VEGF and the increase in EGF and TGF-\(\beta_1\) growth factors. This abnormality in the expression of growth factors is combined with the reduction in the total amount of hairs in the parietal region, change of terminal and vellus hair percentage ratio in the parietal region toward the increase of vellus hair, and violation of normal ratio of anagen and telogen hairs toward the increase of hairs that are in telogen.\textsuperscript{[2]} However, Kubanov et al.\textsuperscript{[3]} studied the expression of growth factors (VEGF, KGF, EGF, and TGF-\(\beta_1\)) in the HF of patients with telogen effluvium and showed that EGF expression was equivalent in these patients and healthy women and did not differ statistically.

Table 3: Comparison between alopecia areata patients epidermal growth factor level as regards severity of the lesion

| Severity | n (%) | EGF | KW | P |
|----------|-------|-----|----|---|
|          | Mean±SD | Minimum-maximum |     |    |
| Mild     | 33 (55) | 28.1±16.7 | 1.80-82 | 23 | 0.0001 |
| Moderate | 17 (28.3) | 38.5±26.5 | 10.7-127.4 |    |    |
| Severe   | 10 (16.7) | 185.6±65.3 | 30.6-232.1 |    |    |

KW – Kruskal-Wallis test; SD – Standard deviation; EGF – Epidermal growth factor

Table 4: Serum epidermal growth factor and severity of alopecia tool score

| Number of patches | n (%) | EGF | KW | P |
|-------------------|-------|-----|----|---|
|                   | Mean±SD | Minimum-maximum |     |    |
| 1                  | 31 (51.7) | 31.2±30.7 | 10.7-187.3 | 23.23 | 0.003 |
| 2                  | 9 (15.0) | 55.18±58.93 | 1.80-161.0 | 14.40-150.0 |
| 3                  | 3 (5.0) | 63.4±375.18 | 32.50-127.4 |
| 4                  | 3 (5.0) | 66.50±52.86 | 34.5-165.0 |
| 5                  | 4 (6.7) | 53.62±27.4 | 15.80-80.0 |
| 6                  | 4 (6.7) | 80.1±57.98 | 132-197.0 |
| 7                  | 3 (5.0) | 164.6±32.5 | 125-194.0 |
| Totalis            | 2 (3.3) | 159.6±48.7 | 82.1-182.0 |
| Universalis        | 1 (1.6) | 232.1 | 232.1 |

Scalp involvement (S)%
| S0 (no hair loss) | 8 (13.3) | 31±26.4 | 1.8-82 | 14.1 | 0.007 |
| S1 (<25% hair loss) | 41 (68.3) | 46.6±53 | 10.7-200.8 |
| S2 (25%-49% hair loss) | 5 (8.3) | 38.2±11.7 | 25.6-56.7 |
| S3 (50%-74% hair loss) | 2 (3.3) | 113.4±117.2 | 30.6-196.3 |
| S4 (75%-99% hair loss) | 4 (6.7) | 221.8±16.8 | 197-232.1 |
| S5 (totals and universalis) | 0 | 0.0 | 0.0 |

Nail involvement (N)%
| N0 (no nail involvement) | 54 (90) | 45.2±52 | 1.8-200.8 | MW=2.6 | 0.009 |
| N1 (some nail involve) | 6 (10) | 165.8±71 | 20.8-232.1 |

Body involvement (B)%
| B0 (no body hair loss) | 48 (80.0) | 60.6±77 | 10.7-232.1 | MW=1.1 | 0.27 |
| B1 (some body hair loss) | 11 (18.3) | 32.7±24.7 | 1.8-82.0 |
| B2 (100% body hair loss) | 1* (1.7) | 232.1 | 232.1-232.1 |

Total involvement
| S0Bn | 8 (13.3) | 41.95±38.99 | 1.8-182.0 | 3.23 | 0.199 |
| SnBo | 48 (80) | 78.23±123.97 | 10.7-800 |
| SnBn | 4 (6.7) | 74.30±105.36 | 17.50-232.10 |

*Excluded from relation (n=1). KW – Kruskal-Wallis test; MW – Mann-Whitney U-test; EGF – Epidermal growth factor; SD – Standard deviation
Against this study, the EGFR downregulation has been linked with HF formation.\textsuperscript{[21,22]} The use of EGFR inhibitors can cause skin inflammation and exacerbation of autoimmune diseases, and these immune-related effects of EGFR inhibitors are due to their direct effects on the expression of the major histocompatibility complex Class I and/or Class II molecules.\textsuperscript{[23]} The roles of the EGF family ligands and receptors, as well as their interplay and physiological phases, have the potential to produce a revolution in the management of hair loss. The availability of topical EGFR blockers and the development of more specific molecules that will stimulate the hair growth pathways will build on the fact that EGFR blockade can produce long-term hair growth. Continuous expression of EGF\textsubscript{r} or TGF\textsubscript{α}, although producing a wavy phenotype, impedes the growth of hair. However cyclic variations in the level of EGFR may result in hair growth and produce new hair formation.\textsuperscript{[12]}

The highest level of mean EGF level in alopecia universalis followed by alopecia totalis then increased number of lesions, the difference statistically significant ($P = 0.003$). The highest level in S\textsubscript{4} hair loss was $221.8 \pm 16.8$ ng/ml. Highest serum level of EGF marker in S\textsubscript{4} (75%-99%) hair loss $221.8 \pm 16.8$ ng/ml then S\textsubscript{3} (50%-74% hair loss) was $113.4 \pm 117.2$ ng/ml, illustrated in table (4) followed by different percentage of hair loss, difference was statistically significant ($P = 0.000$). The EGF level of B\textsubscript{0} was $60.0 \pm 67.7$ and B\textsubscript{1} $32.7 \pm 24.7$ with a statistically insignificant difference ($P = 0.27$), which disagrees with a study done by Wilkening et al.\textsuperscript{[4]} who showed no significant difference associated with any of the SNPs of EGF in patchy or totalis alopecia, but one SNP (rs17337023) of EGFR showed significant differences between patchy-type AA and alopecia totalis ($P < 0.05$).

**CONCLUSIONS**

The normal level of EGF seems to modulate the natural physiological growth of the HF. However, increased EGF signaling intensity produces a reversed effect on HF growth. Elevated growth factors as EGF\textsubscript{r} not always a good sign for hair growth and functioning promotor inducing hair recovery, but it may be linked to the pathogenesis of hair disorders as AA. EGF may be used as a marker of severity, prognosis, and recurrence.

**Acknowledgments**

We are very grateful to all volunteers who took part in this study and the research team who collected the data.

**Financial support and sponsorship**

This was the authors' own work. Laboratory investigations were done in clinical pathology laboratory.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Chen CL, Yu X, James IO, Zhang HY, Yang J, Radulesca A, et al. Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis. Lab Invest 2012;92:331-44.
2. Kabanov A, Yu A, Gallyamova A, Koralev OA. The study of growth factors in patients with androgenic alopecia. Biomed Pharmacol J 2017;10:1219-28.
3. Kabanov AA, Yu A, Koralev OA. A Randomized study of biomimetic peptides efficacy and impact on the growth factors expression in the hair follicles of patients with Telogen Effluvium. J Appl Pharm Sci 2018;8:015-22.
4. Wilkening M, Farcy M, Bauland S, Fourre M, Bazieux F, Denkhadra A. Comparative study of nitrogen savings during enteral and parenteral feeding (Trive 1000). Ann Anasthesiol Fr 1975;16:37-41.
5. Strazzaulla LC, Wang EHC, Avila I, Lo Siceo K, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018;78:1-2.
6. Seeharam KA. Alopecia areata: An update. Indian J Dermatol Venereol Leprol 2013;79:563-75.
7. Ghanaat M. Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. South Med J 2010;103:917-21.
8. Zhang H, Nan W, Wang S, Zhang T, Si H, Yang F, Li G. Epidermal growth factor promotes proliferation and migration of follicular outer root sheath cells via Wnt/β-catenin signaling. Il Physiol Biochem 2016;39:360-70.
9. Mak KK, Chan SY. Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem 2003;278:26120-6.
10. Chen CA, Costa DB, Wu PA. Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline. JAAD Case Rep 2015;1:289-91.
11. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004;51:440-7.
12. Alexandrescu DT, Kaufman CI, Dasanu CA. The cutaneous epidermal growth factor network: Can it be translated clinically to stimulate hair growth? Dermatol Online J 2009;15:1.
13. Wang TH, Chang JI, Ho YH, Wu HC, Chen TC. EphrinA5 suppresses colon cancer development by negatively regulating epidermal growth factor receptor stability. FEBS J 2012;279:251-63.
14. Richardon GJ, Buzi H, Fantauzzo KA, Waters JM, Crawford H, Hynd P, et al. KGF and EGF signalling block hair follicle induction and promote interfollicular epidermal fate in developing mouse skin. Development 2009;136:2153-64.
15. Bichsel KJ, Hammiller B, Trempus CS, Li Y, Hansen LA. The epidermal growth factor receptor decreases Stathmin 1 and triggers catagen entry in the mouse. Exp Dermatol 2016;25:275-81.
16. Moore GPM, Panaretto BA, Carter NB. Epidermal hyperplasia and wool follicle regression in sheep infused with epidermal growth factor. J Invest Dermatol 1985;84:172-5.
17. Luetzteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999;126:2739-50.
18. Philpott MP, Kealey T. Effects of EGF on the morphology and patterns
of DNA synthesis in isolated human hair follicles. J Invest Dermatol 1994;102:186-91.

19. Hansen LA, Alexander N, Hogan ME, Sundberg JP, Dlugosz A, Threadgill DW, et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997;150:1959-75.

20. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-2.

21. Attit R, Conlon RA, Niswander L. EGF signaling patterns the feather array by promoting the interbud fate. Dev Cell 2003;4:231-40.

22. Brown AP, Dunstan RW, Courtney CL, Criswell KA, Graziano MJ. Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Toxicol Pathol 2008;36:410-9.

23. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011;17:4400-13.